Open Payments

Cedars-Sinai Medical Center

Type
Teaching hospital
Where
West Hollywood, CA
Medicare CCN
050625
Received
$20,926,056 in 1,315 records, 2023 ($6,613,461 general, $14,312,595 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2023General payment323$6,613,461
2023Research payment992$14,312,595

By company

CompanyRecordsAmountYears
Siemens Medical Solutions USA, Inc.14$4,437,2342023
Merck Sharp & Dohme LLC47$3,295,7192023
Edwards Lifesciences Corporation70$1,525,9722023
Takeda Pharmaceuticals U.S.A., Inc.81$1,142,6992023
Boston Scientific Corporation54$1,091,9752023
PFIZER INC.48$589,6542023
Kyowa Kirin Co., Ltd2$575,4802023
E.R. Squibb & Sons, L.L.C.17$528,6432023
Genentech, Inc.33$446,9932023
Alkermes, Inc.24$314,1522023
Abbott Laboratories48$312,4012023
VERTEX PHARMACEUTICALS INCORPORATED3$302,3172023
Janssen Research & Development, LLC38$292,3932023
Regeneron Pharmaceuticals, Inc.98$283,5602023
Genmab A/S39$274,7982023
Blueprint Medicines Corporation7$273,7732023
Alnylam Pharmaceuticals Inc.15$265,0312023
Roche Diagnostics Operations, Inc.1$250,0002023
Olympus Corporation of the Americas4$227,5042023
Alexion Pharmaceuticals, Inc.1$182,5752023
Boehringer Ingelheim Pharmaceuticals, Inc.3$175,5652023
Sumitomo Pharma America, Inc.4$157,1992023
ABBVIE INC.27$156,5542023
AstraZeneca Pharmaceuticals LP19$156,4542023
Stryker Corporation16$154,8692023
GENZYME CORPORATION8$144,5122023
Intuitive Surgical, Inc.24$129,8862023
W. L. Gore & Associates, Inc.7$118,2642023
Amgen Inc.2$118,0382023
Novartis Pharmaceuticals Corporation6$105,9732023
SEAGEN INC.16$102,5732023
Ethicon Endo-Surgery Inc.13$101,4232023
MEDIVATION LLC.12$101,0602023
Medtronic, Inc.20$99,6122023
Eli Lilly and Company9$96,1122023
Cardiovascular Systems Inc.4$95,3372023
Janssen Scientific Affairs, LLC3$95,0002023
NuVasive, Inc.2$95,0002023
CSL Behring35$94,2662023
Musculoskeletal Transplant Foundation Inc.7$92,1012023
Penumbra, Inc.15$90,2902023
Exelixis Inc.10$85,9732023
Novocure GmbH5$81,7032023
Intercept Pharmaceuticals, Inc.12$73,3562023
Brahms GmbH18$72,6142023
BioNTech SE23$62,2052023
Medical Device Business Services, Inc.8$54,5602023
Salix Pharmaceuticals, a division of Bausch Health US, LLC5$53,0642023
Orthofix Medical, Inc.2$53,0002023
AstraZeneca UK Limited1$50,0742023

By nature of payment

NatureRecordsAmount
Research payment992$14,312,595
Royalty or License19$4,352,619
Grant88$1,465,855
Space rental or facility fees (teaching hospital only)79$249,358
Education62$221,387
Long term medical supply or device loan23$125,636
Debt forgiveness18$118,901
Compensation for services other than consulting, including serving as faculty or as a speaker at a v27$48,029
Consulting Fee2$19,672
Charitable Contribution5$12,000

Records

DateCompanyAmountNatureFormProductStudyYear
2023-12-31Merck Sharp & Dohme LLC$391,414Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAn Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel2023
2023-12-31Merck Sharp & Dohme LLC$301,597Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAn Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin2023
2023-12-31Merck Sharp & Dohme LLC$285,504Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPilot Study of Immune Checkpoint Inhibition with Pembrolizumab in Advanced BRCA-mutated Breast Cancers2023
2023-12-31Merck Sharp & Dohme LLC$205,590Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA SINGLE-CENTER OPEN-LABEL PROSPECTIVE PILOT STUDY OF POSACONAZOLE IN GENETICALLY-DEFINED PATIENTS WITH ACTIVE CROHN'S D2023
2023-12-31Merck Sharp & Dohme LLC$145,540Research paymentCash or cash equivalent Biological, CARDIOVASCULARA Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for 2023
2023-12-31Siemens Medical Solutions USA, Inc.$109,595Research paymentIn-kind items and servicesEclipse Treatment Planning System for External Beam Radiation Therapy Device, OncologyCardiac RADIoablation versus repeat catheter Ablation: a pivotalrandomized clinical Trial Evaluating safety and efficacy2023
2023-12-31Stryker Corporation$107,773Debt forgivenessCash or cash equivalent2023
2023-12-31Merck Sharp & Dohme LLC$76,999Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT2023
2023-12-31Merck Sharp & Dohme LLC$55,575Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase Ib,II Trial of anti-PD-1 immunotherapy and Stereotactic Radiation in Patients with Recurrent Glioblastoma2023
2023-12-31Merck Sharp & Dohme LLC$55,575Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYReinvigorating TNBC Response to Immunotherapy with Combination Myeloid Inhibition and Radiation2023
2023-12-31Merck Sharp & Dohme LLC$42,919Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2023
2023-12-31Merck Sharp & Dohme LLC$31,993Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment2023
2023-12-31Merck Sharp & Dohme LLC$26,147Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel2023
2023-12-31Merck Sharp & Dohme LLC$22,038Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin2023
2023-12-31Intuitive Surgical, Inc.$16,978Long term medical supply or device loanIn-kind items and servicesDAVINCI XI Device, SURGERY2023
2023-12-31Merck Sharp & Dohme LLC$16,967Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Multicenter, Open-label Phase 2 Study of Lenvatinib E7080,MK-7902 Plus Pembrolizumab MK-3475 in Previously Treated Sub2023
2023-12-31Merck Sharp & Dohme LLC$16,150Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma2023
2023-12-31Merck Sharp & Dohme LLC$13,831Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CAR2023
2023-12-31AngioDynamics, Inc.$13,000Long term medical supply or device loanIn-kind items and servicesSolero Device, Oncology2023
2023-12-31Merck Sharp & Dohme LLC$12,747Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 andPembrolizumab in Combination with2023
2023-12-31KARL STORZ Endoscopy-America$10,886EducationIn-kind items and servicesVITOM Device, MICRO/NOTES/MILITARY2023
2023-12-31Merck Sharp & Dohme LLC$10,713Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w2023
2023-12-31Merck Sharp & Dohme LLC$7,769Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2023
2023-12-31Merck Sharp & Dohme LLC$7,467Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase 3 Study of Pemetrexed Platinum Chemotherapy with or without Pembrolizumab MK-3475 in 2023
2023-12-31Merck Sharp & Dohme LLC$6,222Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as 2023
2023-12-31Brahms GmbH$6,000Research paymentIn-kind items and servicesBRAHMS KRYPTOR compact PLUS (instrument) Device, Kryptor instrumentFirst Trimester Risk Assessment for Preeclampsia study (FITRAPS)2023
2023-12-31Stryker Corporation$5,135Long term medical supply or device loanIn-kind items and servicesEZOUT Device, SURGICAL2023
2023-12-31Intuitive Surgical, Inc.$5,000EducationIn-kind items and servicesDAVINCI XI Device, SURGERY2023
2023-12-31Intuitive Surgical, Inc.$5,000EducationIn-kind items and servicesDAVINCI XI Device, SURGERY2023
2023-12-31Merck Sharp & Dohme LLC$4,828Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w2023
2023-12-31KARL STORZ Endoscopy-America$4,462EducationIn-kind items and servicesIMAGE 1 S Device, VIDEOIMAGING2023
2023-12-31KARL STORZ Endoscopy-America$4,452EducationIn-kind items and servicesIMAGE 1 S Device, VIDEOIMAGING2023
2023-12-31Stryker Corporation$4,087Long term medical supply or device loanIn-kind items and servicesREMB Device, SURGICAL2023
2023-12-31Stryker Corporation$4,045Long term medical supply or device loanIn-kind items and servicesSYSTEM 7 STRYKER PRECISION Device, SURGICAL2023
2023-12-31Stryker Corporation$4,045Long term medical supply or device loanIn-kind items and servicesSYSTEM 7 STRYKER PRECISION Device, SURGICAL2023
2023-12-31Merck Sharp & Dohme LLC$3,552Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CAR2023
2023-12-31Merck Sharp & Dohme LLC$3,483Research paymentIn-kind items and services Biological, CARDIOVASCULARA Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for 2023
2023-12-31KARL STORZ Endoscopy-America$3,235EducationIn-kind items and servicesVITOM Device, MICRO/NOTES/MILITARY2023
2023-12-31Merck Sharp & Dohme LLC$3,078Research paymentIn-kind items and servicesLAGEVRIO Biological, INFECTIOUS DISEASEA Phase 2,3 Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokin2023
2023-12-31Intuitive Surgical, Inc.$2,742Long term medical supply or device loanIn-kind items and servicesDAVINCI XI Device, SURGERY2023
2023-12-31Intuitive Surgical, Inc.$2,742Long term medical supply or device loanIn-kind items and servicesDAVINCI XI Device, SURGERY2023
2023-12-31Stryker Corporation$2,651Long term medical supply or device loanIn-kind items and servicesREMB Device, SURGICAL2023
2023-12-31Merck Sharp & Dohme LLC$2,590Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase 3 Study of Pemetrexed Platinum Chemotherapy with or without Pembrolizumab MK-3475 in 2023
2023-12-31KARL STORZ Endoscopy-America$2,449EducationIn-kind items and servicesIMAGE 1 S Device, VIDEOIMAGING2023
2023-12-31Merck Sharp & Dohme LLC$2,421Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as 2023
2023-12-31AstraZeneca Pharmaceuticals LP$2,292Research paymentIn-kind items and servicesTAGRISSO Drug, OncologyTo assess the efficacy and safety of AZD9291 versus Placebo in patients with Epidermal Growth Factor Receptor Mutation P2023
2023-12-31KARL STORZ Endoscopy-America$2,289EducationIn-kind items and servicesVITOM Device, MICRO/NOTES/MILITARY2023
2023-12-31Stryker Corporation$2,217Long term medical supply or device loanIn-kind items and servicesREMB Device, SURGICAL2023
2023-12-31Merck Sharp & Dohme LLC$2,193Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYAn Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment2023
2023-12-31KARL STORZ Endoscopy-America$2,164EducationIn-kind items and servicesIMAGE 1 S Device, VIDEOIMAGING2023
2023-12-31KARL STORZ Endoscopy-America$2,079EducationIn-kind items and servicesVITOM Device, MICRO/NOTES/MILITARY2023
2023-12-31KARL STORZ Endoscopy-America$1,373EducationIn-kind items and services2023
2023-12-31Merck Sharp & Dohme LLC$1,364Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 andPembrolizumab in Combination with2023
2023-12-31Merck Sharp & Dohme LLC$1,170Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose C2023
2023-12-31Stryker Corporation$1,114Debt forgivenessCash or cash equivalent2023
2023-12-31ABBVIE INC.$1,056Research paymentIn-kind items and servicesStudy To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In2023
2023-12-31Merck Sharp & Dohme LLC$1,029Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma2023
2023-12-31KARL STORZ Endoscopy-America$943EducationIn-kind items and services2023
2023-12-31KARL STORZ Endoscopy-America$860EducationIn-kind items and services2023
2023-12-31Stryker Corporation$741Long term medical supply or device loanIn-kind items and servicesSTRYKER Device, SURGICAL2023
2023-12-31Medline Industries LP$644Debt forgivenessCash or cash equivalent2023
2023-12-31KARL STORZ Endoscopy-America$643EducationIn-kind items and servicesVITOM Device, MICRO/NOTES/MILITARY2023
2023-12-31KARL STORZ Endoscopy-America$469EducationIn-kind items and servicesIMAGE 1 S Device, VIDEOIMAGING2023
2023-12-31ABBVIE INC.$450Research paymentIn-kind items and servicesA Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumor2023
2023-12-31KARL STORZ Endoscopy-America$448EducationIn-kind items and servicesVITOM Device, MICRO/NOTES/MILITARY2023
2023-12-31KARL STORZ Endoscopy-America$435EducationIn-kind items and services2023
2023-12-31Merck Sharp & Dohme LLC$435Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg2023
2023-12-31KARL STORZ Endoscopy-America$409EducationIn-kind items and servicesIMAGE 1 S Device, VIDEOIMAGING2023
2023-12-31KARL STORZ Endoscopy-America$394EducationIn-kind items and services2023
2023-12-31KARL STORZ Endoscopy-America$394EducationIn-kind items and servicesVITOM Device, MICRO/NOTES/MILITARY2023
2023-12-31AstraZeneca Pharmaceuticals LP$392Research paymentIn-kind items and servicesA Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progr2023
2023-12-31ENCORE MEDICAL, LP$321Debt forgivenessCash or cash equivalent2023
2023-12-31KARL STORZ Endoscopy-America$307EducationIn-kind items and servicesVITOM Device, MICRO/NOTES/MILITARY2023
2023-12-31KARL STORZ Endoscopy-America$291EducationIn-kind items and services2023
2023-12-31Edwards Lifesciences Corporation$223Long term medical supply or device loanIn-kind items and servicesHemoSphere Device, Hemodynamic Monitoring2023
2023-12-31KARL STORZ Endoscopy-America$218EducationIn-kind items and servicesVITOM Device, MICRO/NOTES/MILITARY2023
2023-12-31AstraZeneca Pharmaceuticals LP$213Research paymentIn-kind items and servicesIMFINZI Biological, OncologyThis is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus2023
2023-12-31AstraZeneca Pharmaceuticals LP$161Research paymentIn-kind items and servicesLYNPARZA Drug, Oncology\";A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in P2023
2023-12-31KARL STORZ Endoscopy-America$122EducationIn-kind items and servicesVITOM Device, MICRO/NOTES/MILITARY2023
2023-12-31Medline Industries LP$117Debt forgivenessCash or cash equivalent2023
2023-12-31KARL STORZ Endoscopy-America$96EducationIn-kind items and servicesVITOM Device, MICRO/NOTES/MILITARY2023
2023-12-31ABBVIE INC.$88Research paymentIn-kind items and servicesBOTOX Biological, FACIAL AESTHETICSStudy of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Inte2023
2023-12-31Medline Industries LP$81Debt forgivenessCash or cash equivalent2023
2023-12-31KARL STORZ Endoscopy-America$55EducationIn-kind items and services2023
2023-12-31KARL STORZ Endoscopy-America$49EducationIn-kind items and servicesIMAGE 1 S Device, VIDEOIMAGING2023
2023-12-31KARL STORZ Endoscopy-America$47EducationIn-kind items and services2023
2023-12-31Stryker Corporation$43Debt forgivenessCash or cash equivalent2023
2023-12-31KARL STORZ Endoscopy-America$22EducationIn-kind items and servicesVITOM Device, MICRO/NOTES/MILITARY2023
2023-12-31Stryker Corporation$13Debt forgivenessCash or cash equivalent2023
2023-12-31KARL STORZ Endoscopy-America$12EducationIn-kind items and servicesVITOM Device, MICRO/NOTES/MILITARY2023
2023-12-31KARL STORZ Endoscopy-America$10EducationIn-kind items and servicesVITOM Device, MICRO/NOTES/MILITARY2023
2023-12-31KARL STORZ Endoscopy-America$9EducationIn-kind items and servicesVITOM Device, MICRO/NOTES/MILITARY2023
2023-12-31KARL STORZ Endoscopy-America$8EducationIn-kind items and servicesIMAGE 1 S Device, VIDEOIMAGING2023
2023-12-28KARL STORZ Endoscopy-America$4,733EducationIn-kind items and services2023
2023-12-27Abbott Laboratories$760Research paymentCash or cash equivalentJETI PERIPHERAL CATHETER Device, VascularJETi Peripheral Thrombectomy Registry (JETi)2023
2023-12-27KARL STORZ Endoscopy-America$285EducationIn-kind items and services2023
2023-12-27KARL STORZ Endoscopy-America$23EducationIn-kind items and services2023
2023-12-25AstraZeneca Pharmaceuticals LP$2,750Space rental or facility fees (teaching hospital only)Cash or cash equivalentANDEXXA Biological, Rare Disease2023
2023-12-25Ethicon Endo-Surgery Inc.$400Research paymentCash or cash equivalentEchelon; Endopath Device, Endo-MechanicalA Multi-Center Evaluation of the ECHELONT 3000 (Next Generation Powered Stapler) in Laparoscopic Sleeve Gastrectomy and 2023
2023-12-25Ethicon Endo-Surgery Inc.$390Research paymentCash or cash equivalentEchelon; Endopath Device, Endo-MechanicalA Multi-Center Evaluation of the ECHELONT 3000 (Next Generation Powered Stapler) in Laparoscopic Sleeve Gastrectomy and 2023
2023-12-25Ethicon Endo-Surgery Inc.$250Research paymentCash or cash equivalentEchelon; Endopath Device, Endo-MechanicalA Multi-Center Evaluation of the ECHELONT 3000 (Next Generation Powered Stapler) in Laparoscopic Sleeve Gastrectomy and 2023
2023-12-22W. L. Gore & Associates, Inc.$5,084Research paymentCash or cash equivalentProduct in Development Device, DevicesEvaluation of the GORE TAG Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch an2023
2023-12-22Biosense Webster, Inc.$900Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-12-22Janssen Research & Development, LLC$831Research paymentCash or cash equivalentA Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Co2023
2023-12-22Biosense Webster, Inc.$800Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-12-22Biosense Webster, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-12-21Edwards Lifesciences Corporation$100,000GrantCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves2023
2023-12-21Veloxis Pharmaceuticals, Inc.$23,554Research paymentCash or cash equivalentENVARSUS Drug, TRANSPLANTATIONA PROSPECTIVE, PILOT TRIAL TO COMPARE THE EFFICACY OF TACROLIMUS EXTENDED-RELEASE (ENVARSUS XR) TO TACROLIMUS IMMEDIATE-2023
2023-12-21Blueprint Medicines Corporation$9,092Research paymentCash or cash equivalentBLU-945-11012023
2023-12-21Janssen Research & Development, LLC$3,700Research paymentCash or cash equivalentAn Open label Multi Center Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Deli2023
2023-12-21Fisher Scientific Company L.L.C.$12Research paymentIn-kind items and servicessFlt-1 Device, prenatal screeningIdentification and validation of a cut-off for the ratio of suluble Fms-like Tyrosine Kinase-1 to Placental Growth Facto2023
2023-12-20Merz Pharmaceuticals, LLC$5,000GrantCash or cash equivalent2023
2023-12-20Genmab A/S$3,017Research paymentCash or cash equivalentEpkinly Drug, OncologyA Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) 2023
2023-12-20Genmab A/S$3,017Research paymentCash or cash equivalentEpkinly Drug, OncologyA Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) 2023
2023-12-20Genmab A/S$2,977Research paymentCash or cash equivalentEpkinly Drug, OncologyA Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) 2023
2023-12-20Genmab A/S$2,950Research paymentCash or cash equivalentEpkinly Drug, OncologyA Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) 2023
2023-12-20Genmab A/S$2,885Research paymentCash or cash equivalentEpkinly Drug, OncologyA Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) 2023
2023-12-20Brahms GmbH$2,505Research paymentIn-kind items and servicesBRAHMS sFlt-1 KRYPTOR kits, CAL and QC Device, prenatal screeningFirst Trimester Risk Assessment for Preeclampsia study (FITRAPS)2023
2023-12-20W. L. Gore & Associates, Inc.$2,358Research paymentCash or cash equivalentProduct in Development Device, DevicesEvaluation of the GORE TAG Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch an2023
2023-12-20Genmab A/S$2,031Research paymentCash or cash equivalentEpkinly Drug, OncologyA Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) 2023
2023-12-20Genmab A/S$1,790Research paymentCash or cash equivalentEpkinly Drug, OncologyA Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) 2023
2023-12-20Genmab A/S$1,725Research paymentCash or cash equivalentEpkinly Drug, OncologyA Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) 2023
2023-12-20Genmab A/S$1,725Research paymentCash or cash equivalentEpkinly Drug, OncologyA Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) 2023
2023-12-20Grifols Biologicals LLC$1,373Research paymentIn-kind items and servicesAlbutein Biological, Critical Care MedicineEffects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With Acute-On-Chroni2023
2023-12-20Genmab A/S$442Research paymentCash or cash equivalentEpkinly Drug, OncologyA Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) 2023
2023-12-20Genmab A/S$442Research paymentCash or cash equivalentEpkinly Drug, OncologyA Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) 2023
2023-12-18Ethicon Endo-Surgery Inc.$20,046Research paymentCash or cash equivalentEchelon; Endopath Device, Endo-MechanicalA Multi-Center Evaluation of the ECHELONT 3000 (Next Generation Powered Stapler) in Laparoscopic Sleeve Gastrectomy and 2023
2023-12-18Boston Scientific Corporation$15,119Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product ICACURATE IDE2023
2023-12-18Synthes GmbH$10,000GrantCash or cash equivalent2023
2023-12-18Boston Scientific Corporation$7,033Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product PIELEGANCE2023
2023-12-18Medical Device Business Services, Inc.$5,000GrantCash or cash equivalent2023
2023-12-18PROGENICS PHARMACEUTICALS, INC.$4,927Research paymentCash or cash equivalentPYLARIFY Drug, RADIOPHARMACEUTICALHIGH-RESOLUTION, 18F-PSMA PET-MRI FOR MAPPING PROSTATE CANCER IN PATIENTS CONSIDERING FOCAL HIGH-INTENSITY FOCUSED ULTRA2023
2023-12-18Boston Scientific Corporation$1,560Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product PIHI PEITHO2023
2023-12-18Janssen Research & Development, LLC$623Research paymentCash or cash equivalentERLEADA Drug, OncologyA Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locall2023
2023-12-15Grifols Biologicals LLC$2,747Research paymentIn-kind items and servicesAlbutein Biological, Critical Care MedicineEffects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With Acute-On-Chroni2023
2023-12-14Regeneron Pharmaceuticals, Inc.$9,613Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$5,337Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$4,497Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14ABBVIE INC.$4,405Research paymentCash or cash equivalentBOTOX Biological, FACIAL AESTHETICSStudy of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Inte2023
2023-12-14Regeneron Pharmaceuticals, Inc.$1,974Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$1,705Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$1,413Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Medtronic, Inc.$819Research paymentCash or cash equivalentINFUSE BONE GRAFT Device, Bone Matrix/GraftTLIF IDE Pivotal Study2023
2023-12-14PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2023
2023-12-14PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2023
2023-12-14PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2023
2023-12-14Regeneron Pharmaceuticals, Inc.$100Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$100Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$100Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$100Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$100Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$87Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$87Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$87Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$79Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$79Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$79Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$58Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$58Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$33Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$31Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$31Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$31Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$31Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$24Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$24Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$24Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$24Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$18Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$18Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$18Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$18Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$17Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$17Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$15Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$15Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$15Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$15Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$10Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-14Regeneron Pharmaceuticals, Inc.$10Research paymentCash or cash equivalentA Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat2023
2023-12-13Merck Sharp & Dohme LLC$205,144Research paymentCash or cash equivalentWELIREG Drug, ONCOLOGYA Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w2023
2023-12-13Merck Sharp & Dohme LLC$179,451Research paymentCash or cash equivalentWELIREG Drug, ONCOLOGYAn Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin2023
2023-12-13SEAGEN INC.$10,000GrantCash or cash equivalent2023
2023-12-13Takeda Pharmaceuticals U.S.A., Inc.$3,197Research paymentCash or cash equivalentRELAPSED OR REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (NHL)2023
2023-12-13Gilead Sciences, Inc.$2,950Space rental or facility fees (teaching hospital only)Cash or cash equivalent2023
2023-12-11GENZYME CORPORATION$20,000GrantCash or cash equivalent2023
2023-12-11Janssen Research & Development, LLC$6,624Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2023
2023-12-11GENZYME CORPORATION$4,186Research paymentCash or cash equivalentDUPIXENT Biological, ImmunologyA Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With2023
2023-12-08Incyte Corporation$2,660Research paymentCash or cash equivalentA Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participan2023
2023-12-07Alnylam Pharmaceuticals Inc.$10,000GrantCash or cash equivalent2023
2023-12-07ABBVIE INC.$7,550Research paymentCash or cash equivalentBOTOX Biological, FACIAL AESTHETICSStudy of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Inte2023
2023-12-07PROGENICS PHARMACEUTICALS, INC.$4,927Research paymentCash or cash equivalentPYLARIFY Drug, RADIOPHARMACEUTICALHIGH-RESOLUTION, 18F-PSMA PET-MRI FOR MAPPING PROSTATE CANCER IN PATIENTS CONSIDERING FOCAL HIGH-INTENSITY FOCUSED ULTRA2023
2023-12-07Premia Spine, Ltd.$2,398Research paymentCash or cash equivalentTOPSA Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System2023
2023-12-06Alnylam Pharmaceuticals Inc.$15,764Research paymentCash or cash equivalentONPATTRO Drug, Genetic DiseaseAPOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety 2023
2023-12-06Takeda Pharmaceuticals U.S.A., Inc.$5,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2023
2023-12-06ABBVIE INC.$1,950Research paymentCash or cash equivalentA Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and or Refractory Solid Tumor2023
2023-12-05ABBVIE INC.$2,275Research paymentCash or cash equivalentA Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and or Refractory Solid Tumor2023
2023-12-05ABBVIE INC.$2,275Research paymentCash or cash equivalentA Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and or Refractory Solid Tumor2023
2023-12-05Travere Therapeutics, Inc.$1,950Research paymentCash or cash equivalent021FSGS160102023
2023-12-05Travere Therapeutics, Inc.$1,690Research paymentCash or cash equivalent021FSGS160102023

The latest 200 records of 1,315.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Los Angeles CountyWest Hollywood city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In West Hollywood, CA, county Los Angeles County, CA, state California; placed by its city name.

MeasurePlace (city or town)
West Hollywood, CA
County
Los Angeles County, CA
State
California
Population B0100334,8849,808,66739,287,377
Population, 2020 census P135,75710,014,00939,538,223
Median age B0100240.038.237.9
Under 18 B010013.6%20.6%22.0%
65 and over B0100116.8%15.2%15.7%
Households B1100122,9203,416,44913,548,091
Foreign born B0500223.6%33.4%27.0%
Median household income B19013$96,995$90,112$99,122
Median family income B19113$126,364$101,573$113,346
Per capita income B19301$90,080$45,792$49,513
Poverty rate B1700112.9%13.7%12.0%
Unemployment rate B230258.9%7.3%6.6%
Civilian labor force B2302525,8185,200,65620,068,466
Mean commute (minutes) B0801327.130.428.7
Bachelor's degree or higher B1500364.2%36.0%37.1%
Housing units B2500126,0793,650,46614,644,735
Owner-occupied B2500319.8%45.9%55.9%
Renters B2500380.2%54.1%44.1%
Median home value B25077$924,800$834,200$734,700
Median gross rent B25064$2,091$1,954$2,036
White, not Hispanic B0300269.5%24.7%33.8%
Black B030024.3%7.4%5.2%
Hispanic or Latino B0300213.1%48.4%40.2%
Asian B030026.1%14.9%15.3%
American Indian and Alaska Native B030020.1%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in West Hollywood, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.